Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

nd individual investigators as a single agent or as a combination treatment in a wide range of cancers, including lung, thyroid, breast, ovarian, and colorectal cancer and as an adjuvant therapy for liver and kidney cancer. 

Important Safety Considerations For Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma and advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed.  In HCC patients, bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo.  The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo.  In RCC patients, incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo.  Most common adverse events >/=20% related to Nexavar for both HCC and RCC were fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhea, nausea, and abdominal pain.  Grade 3/4 adverse events in HCC and RCC patients, respectively, were 45% for Nexavar vs. 32% for placebo and 38% for Nexavar and 28% for placebo.  Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding.  In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... The report provides qualitative insights on ... sub-segments of the market, in order to provide information ... rates and market sizes for each sub-segment of the ... growth. It also includes analysis of the company profiles ... the financial performances, product portfolios, and developments of each ...
(Date:11/27/2014)... The Europe Thermal Protective Clothing ... provide crucial revenue forecasts. It estimates the market ... a CAGR of 7.5%, from 2013 to 2018. ... Thermal Protective Clothing market report for a glimpse ... by various tables and figures. , http://www.micromarketmonitor.com/market/europe-thermal-protective-clothing-5957050557.html ...
(Date:11/27/2014)... -- Research and Markets  has announced ... Report 2014" report to their offering. ... Palmitic Acid Industry Report 2014 is a professional and ... palmitic acid industry. The report provides a ... and industry chain structure. The palmitic acid market analysis ...
(Date:11/27/2014)... Spartan Bioscience today announced that it ... Safety (MFDS) regulatory approval for its Spartan RX ... less than 60 minutes from a non-invasive cheek swab. ... for doctors to determine therapeutic strategies for drugs metabolized ... of the world’s most commonly prescribed drugs such as ...
Breaking Biology Technology:Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 2Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 3Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 4Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 5The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Global Palmitic Acid Industry Report 2014 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3
... of Ablation Therapy Using HALO System Demonstrated for, ... Progression, SAN DIEGO, May 19 Booth ... a technology leader in the design and manufacture,of ... presentation,of a landmark study entitled, "A Randomized, Multicenter, ...
... size allows for treatment of smaller-diameter diseased saphenous vein ... ... Boston Scientific,Corporation (NYSE: BSX ) today announced the launch of its ... designed to contain,and remove embolic material that may be dislodged during an ...
... 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ), ... and marketing biopharmaceutical products,primarily in China, will present ... in New York on Thursday, May 22, 2008 ... webcast live and can be accessed on the,Webcasts ...
Cached Biology Technology:Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus 2Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus 3Boston Scientific Announces Launch of Expanded Size Range of FilterWire EZ(TM) Embolic Protection System 2Boston Scientific Announces Launch of Expanded Size Range of FilterWire EZ(TM) Embolic Protection System 3Boston Scientific Announces Launch of Expanded Size Range of FilterWire EZ(TM) Embolic Protection System 4
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws ... efficiency are piloting the North American and European automotive ... accidents growing, gesture recognition systems that are intuitive and ... mark in the industry. New analysis ... Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... computation of haplotypes provides insight into genetic basis of ... map of genetic variation which can give clues to ... technologies collect genotypes, or information from the individual's ... to the variations between individuals' DNA at the level ...
... figured out the fate of healthy protein when it ... yeast: The protein converts to the prion form, rendering ... , This quick-change "mating" maneuver sheds important light on ... cause fatal brain ailments such as mad cow disease ...
... virus in tissues from patients who died of a ... the strain of virus in the measles vaccine caused ... issue of The Journal of Infectious Diseases, now available ... many more cases of the disease, known as subacute ...
Cached Biology News:U-M scientists say fused genes trigger the development of prostate cancer 2U-M scientists say fused genes trigger the development of prostate cancer 3U-M scientists say fused genes trigger the development of prostate cancer 4Prions rapidly 'remodel' good protein into bad, Brown study shows 2New study shows measles immunization may prevent fatal brain infection 2